Відео

DDW's Megan Thomas interviews Dr Rohan Thakur, President of Bruker Daltonics, as part of the From the Top vodcast series. Dr Thakur discusses the intersection of science and business, sharing his experiences and insights on how to navigate this intersection. He reflects on his career path, highlighting key moments and milestones, and expresses gratitude for the opportunities he has had. He also...

The latest DDW Sitting Down With sponsored vodcast features Dr Adriano Flora, Director of Business Development at The Jackson Laboratory (JAX). In this vodcast, Dr Flora discusses: • Alternatives to non-human primates • Key benefits of this • What impact will they have on the future of drug development • Key breakthroughs in recent years in this field • How have these impacted future success • ...

At the American Association of Cancer Research’s Annual Meeting in Orlando, Florida (AACR 2023), DDW’s Megan Thomas met with industry experts to learn more about their research and careers in the field of cancer research. In this vodcast episode, Thomas speaks with Dennis Brown, Chief Scientific Officer at Kintara Therapeutics.

Clinical stage oncology company Avacta Group has moved its Therapeutics division to a new headquarters at Scale Space in Imperial College’s White City Campus, London. DDW Multimedia Editor Megan Thomas attended the open day to learn more about the company’s intentions. In this video, she speaks to Neil Bell, Chief Development Officer at Avacta and Dr Fiona McLaughlin, Chief Scientific Officer a...

Lithuania is dedicating time and resources establishing itself as a life sciences and biotechnology hub of excellence. DDW’s Megan Thomas analyses four pillars of Lithuania’s growth strategy, which involves ensuring female scientists take leading roles in industry, focusing on investment, developing a strong talent pool as well establishing itself as a go-to destination for clinical trials.

The COVID Moonshot is a global consortium that aims to rapidly develop antivirals for COVID-19. Dr. Lizbe Koekemoer of Oxford University describes how the project team leverages the CDD Vault informatics platform to effectively store, manage, and share data among multiple international partners.

Non-alcoholic fatty liver disease (NAFLD) has quietly become one of the most common causes of chronic liver disease in the modern world. If this prevalence is allowed to continue the economic and clinical burden will reach a staggering level. Non-alcoholic fatty liver disease (NAFLD) consists of a complex combination of liver maladies, ranging from benign hepatic steatosis (fatty liver) to its ...

This article will describe, with examples, how understanding the likely mechanisms of false positives in advance of screening informs the design of the hit triage, thus increasing the likelihood of discovering optimisable chemical matter and avoiding costly wasting of resource. We describe the use of a bespoke ‘Robustness Set’ of nuisance compounds and how it can be used in conjunction with adj...

The emergence of SARS-CoV-2 virus and the disease it causes, COVID-19, have fuelled significant shifts in preclinical research across the globe. Amid the worldwide health emergency created by high infection rates, rapid transmission spread and relatively high mortality rates, researchers are under pressure to understand the disease’s pathogenesis, develop and test investigational therapeutics a...

Cryo-electron microscopy (cryo-EM), a powerful biophysical technique that can analyse molecular assemblies, is changing the paradigm in structure-based drug design. As targets become more challenging, solving structures of drug target molecules or biologics becomes increasingly difficult. Cryo-EM empowers drug discovery teams to take advantage of rational drug design for many more major drug ta...

In this episode, we discuss the oxymoronic proposition of a Virtual Pharmaceutical Company (VPC) and the typical adopted business model, as well as provide examples of such companies currently trying to undertake this adventurous task. The vagaries and complexities of bringing a therapeutic drug to market through the Drug Discovery and Development (DDD) process are well known and described. Any...

Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This two part article series examines the major initiatives being explored at the public policy level to contain the spread of COVID-19 as well as some of th...

Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This 2 part episode series examines the major initiatives being explored at the public policy level to contain the spread of COVID-19 as well as some of the ...

The recent outbreak of COVID-19 has highlighted the need for fast and efficient development and production of vaccines for a whole gamut of pathogens, old and new. Microfluidics technologies can be used to accelerate the vaccine development process in a number of ways, not least in the directed evolution of the strains and host organisms used in the production of vaccines based on recombinant D...

The COVID-19 antiviral race: we're all in this together

Using Live-Cell Imaging Systems to Transform Perspectives in Drug Discovery

Fail Early, Fail Fast - A phenotypic rescue approach

Unlocking Clinical Trial Data to Uncover New Therapeutic Opportunities

From human genome to global genome - why precision medicine must address genetic diversity

Optimising Phenotypic Screening - Single-cell analysis versus 3D multicell analysis

How Artificial Intelligence is Transforming Drug Design

Safety First - Automating cell line development

Application of bioinformatics in support of precision medicine

3D Organoid Cell Culture - Optimising disease models for research and drug discovery

Bitten by the Bug - A flurry of investments fuel microbiome drug discovery

From Genotype to Phenotype: Leveraging functional genomics in oncology

Flow Cytometry - The advanced systems overcoming drug discovery pain points

Cell Therapy - Falling short of its potential?

Fostering Multidisciplinary Collaboration in Drug Discovery